Predicting treatment response to intra-arterial therapies for hepatocellular carcinoma with the use of supervised machine learning—an artificial intelligence concept

A Abajian, N Murali, LJ Savic, FM Laage-Gaupp… - Journal of Vascular and …, 2018 - Elsevier
Purpose To use magnetic resonance (MR) imaging and clinical patient data to create an
artificial intelligence (AI) framework for the prediction of therapeutic outcomes of transarterial …

Optimization of the BCLC staging system for locoregional therapy for hepatocellular carcinoma by using quantitative tumor burden imaging biomarkers at MRI

T Borde, N Nezami, F Laage Gaupp, LJ Savic, T Taddei… - Radiology, 2022 - pubs.rsna.org
Background Patients with intermediate-and advanced-stage hepatocellular carcinoma
(HCC) represent a highly heterogeneous patient collective with substantial differences in …

[HTML][HTML] Post locoregional therapy treatment imaging in hepatocellular carcinoma patients: a literature-based review

S Young, AJ Taylor, T Sanghvi - Journal of Clinical and …, 2018 - ncbi.nlm.nih.gov
Imaging plays a crucial role in the diagnosis of hepatocellular carcinoma (HCC) as well as in
determining treatment efficacy, or complications, following therapy. Unlike other cancers …

Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach

V Tacher, MD Lin, R Duran, H Yarmohammadi, H Lee… - Radiology, 2016 - pubs.rsna.org
Purpose To compare currently available non–three-dimensional methods (Response
Evaluation Criteria in Solid Tumors [RECIST], European Association for Study of the Liver …

Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole …

S Sahu, R Schernthaner, R Ardon, J Chapiro, Y Zhao… - Radiology, 2017 - pubs.rsna.org
Purpose To investigate whether whole-liver enhancing tumor burden [ETB] can serve as an
imaging biomarker and help predict survival better than World Health Organization (WHO) …

Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria

M Ghosn, H Derbel, R Kharrat, N Oubaya… - Diagnostic and …, 2021 - Elsevier
Purpose To evaluate the potential of imaging criteria in predicting overall survival of patients
with hepatocellular carcinoma (HCC) after a first transcatheter arterial yttrium-90 …

Intra-arterial therapies for liver cancer: assessing tumor response

YW Stroehl, BS Letzen, JMM van Breugel… - Expert Review of …, 2017 - Taylor & Francis
ABSTRACT Introduction: Intra-arterial therapies (IATs) play an integral role in the
management of unresectable hepatocellular carcinoma and liver metastases. The ability to …

Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial

BS Letzen, R Malpani, M Miszczuk, QMB de Ruiter… - Clinical imaging, 2021 - Elsevier
Background The use of the ethiodized oil-Lipiodol in conventional trans-arterial
chemoembolization (cTACE) ensures radiopacity to visualize drug delivery in the process of …

Predictive modeling for voxel-based quantification of imaging-based subtypes of pancreatic ductal adenocarcinoma (PDAC): a multi-institutional study

M Zaid, L Widmann, A Dai, K Sun, J Zhang, J Zhao… - Cancers, 2020 - mdpi.com
Simple Summary Previously, we demonstrated that qualitative scoring of pancreatic ductal
adenocarcinoma (PDAC) tumors on computed tomography (CT) scans (delta) is biologically …

3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as …

FN Fleckenstein, RE Schernthaner, R Duran… - European …, 2016 - Springer
Objectives To compare the ability of single-vs. multi-lesion assessment on baseline MRI
using 1D-and 3D-based measurements to predict overall survival (OS) in patients with …